1382. Dengue Fever: From Disease to Vaccination - A Pediatric Perspective
Session: Symposium: Emerging and Retreating Mosquito-Borne Infections
Sunday, October 23, 2011: 7:30 AM
Room: 253ABC

Harold Margolis, MD, FIDSA, Centers for Disease Control and Prevention, Atlanta, GA

Harold S. Margolis, MD, FAAP, FIDSA is Chief, Dengue Branch, Centers for Disease Control (CDC) and Prevention, San Juan, Puerto Rico. From 2004-2010 he was Director of the Pediatric Dengue Vaccine Initiative (PDVI), a program of the International Vaccine Institute, Seoul, Korea. A graduate of the University of Arizona College of Medicine, Dr. Margolis completed a residency in pediatrics at the University of Colorado Health Sciences Center and Denver Childrenís Hospital and is a fellow of the American Academy of Pediatrics (AAP). In 1975, he joined CDC as an Epidemic Intelligence Service (EIS) Officer and in 1987 became director of CDCís viral hepatitis research and prevention program and director of the World Health Organization Collaborating Center for Research and Reference in Viral Hepatitis. While at CDC, Dr. Margolis led development and implementation of CDCís hepatitis B and hepatitis A immunization programs, and the national program to prevent and control hepatitis C. As Director of CDCís Division of Vial Hepatitis, he implemented programs in epidemiology, vaccine evaluation, public health and laboratory science. He was the architect of US immunization recommendations to eliminate hepatitis B virus transmission and of the WHO hepatitis B immunization program. During 2001-2002 he was CDCís Senior Advisor for Smallpox Preparedness and Response. During his time as Director of the PDVI, this product devlopment partnership worked with dengue vaccine developers to ensure that multiple candidates entered clinical trials, established field sites to determine disease incidence and prepare for large-scale clinical trials of dengue vaccines, and supported evaluation and improvement of dengue diagnostics for pre- and post licensure vaccine evaluation. Dr. Margolis has been a frequent advisor to WHO and other international health agencies on introduction of hepatitis B vaccine into national immunization programs, control of bloodborne pathogens transmitted through unsafe injection and medical practices, control of hepatitis C, and dengue vaccine development and evaluation. He is the author or co-author of over 200 peer reviewed publications.

Previous Presentation | Next Presentation >>

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.